<DOC>
	<DOC>NCT01742221</DOC>
	<brief_summary>This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.</brief_summary>
	<brief_title>Safety and Tolerability of HemaMaxâ„¢ (rHuIL-12) as Radiation Countermeasure</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Radiation Syndrome</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>Male and Female subjects, who have signed the informed consent form must meet all of the following criteria 1. 18 to 45 years of age 2. Body mass index (BMI) &gt; 19 and &lt; 0 kg/m2 3. Normal ECG, vital signs and laboratory test results 4. Use of effective birth control method and abstinence from sex 5. Negative pregnancy test and drug screen Subjects with any of the following characteristics will be considered ineligible: 1. History of clinically significant renal, hepatic pulmonary, cardiovascular, cerebrovascular, gastrointestinal, metabolic, hematological, endocrine, urological, immunological, neurologic or psychiatric disorders or connective tissue disease 2. Positive for human immunodeficiency virus (HIV), Hepatitis B, or surface antigen (HBsAg) or Hepatitis C antibody, tuberculosis (TB) 3. Current drug or alcohol addiction 4. History of clinically significant allergy of any kind 5. Prior use of IL12 or HemaMax 6. Use of any approved or investigational biologic agents or vaccinations of any kind in last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Safety and Tolerability, Cytokines, Acute Radiation Syndrome, Hematopoietic Syndrome, Radiation Countermeasure</keyword>
</DOC>